Abbott bumps up profit forecast on strong medical device sales The World Health Organization ... son developed after the hospital fed him the companies' formulas. Jury urged to hold formula ...

CNBC's Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that's been weighed down by hefty lawsuits.

The company saw strong growth for its medical devices business, while diagnostics sales trended lower. In this note, we discuss Abbott’s stock performance, key takeaways from its recent results ...

With a market cap of $202.2 billion, North Chicago, Illinois-based Abbott Laboratories (ABT) is a global healthcare company.

US medical device company Abbott has said it plans to launch a new range of 'biowearable' health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring.

Shares of Abbott rose 2% in afternoon trade. The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion ...

Abbott Laboratories beat third-quarter profit ... midpoint of its profit outlook on strong demand for its medical devices. The company posted third-quarter earnings per share (EPS) of 94 cents ...

Oct 16 (Reuters) - Abbott Laboratories (ABT.N), opens new tab slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand ...

I reiterate a “Strong Buy” rating for Abbott Laboratories with a fair value of $135 per share due to their strong R&D pipeline and robust financial performance. Abbott's recent results show 7. ...

Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company’s medical-devices business. The Abbott Park, Ill.-based ...

Sales growth in the medical devices segment drove Abbott Laboratories’ expectations-beating revenue in the past financial quarter as the company faces lower demand for COVID-19 tests ...

The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion, according to data compiled by LSEG.